Tech Company M&A Transactions
Monogram Biosciences Acquisition
Monogram Biosciences, operating out of South San Francisco, was acquired by Aclara Biosciences. The transaction price was $75 million.
Transaction Overview
Company Name
Acquired By
Announced On
6/1/2004
Transaction Type
M&A
Amount
$75,000,000
M&A Terms
ACLARA common stock will be exchanged for 1.7 shares of ViroLogic common stock and 1.7 contingent value rights (CVR). The common stock portion of the consideration equals $4.78 per share of ACLARA based on ViroLogic's closing price of $2.81 on May 28. In addition to receiving shares of ViroLogic, the CVR provides for a potential cash payment of up to $0.50 per CVR (equivalent to $0.85 per ACLARA share) depending on the ViroLogic stock price twelve months following completion of the merger. After the closing of the merger, ViroLogic expects to have approximately $75 million in cash.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
345 Oyster Point Blvd.
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Monogram Biosciences is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven Anderson
VP - Operations
Jeanette Whitcomb
VP - R & D
Christos Petropoulos
Browse more venture capital transactions:
Prev: 6/1/2004: Cortera venture capital transaction
Next: 6/1/2004: Virtusa venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs